Difference between revisions of "Research:Coronavirus vaccine"
(changed doi links to normal links and fixed examples) |
(complying with new guidelines) |
||
| Line 1: | Line 1: | ||
== Research == | == Research == | ||
=== | === Variants and synonyms === | ||
* COVID-19 vaccine | * COVID-19 vaccine | ||
| Line 12: | Line 10: | ||
Efforts to design a coronavirus vaccine have focused on a variety of approaches including development of inactivated virus, live-attenuated virus, and a variety of subunit vaccines. | Efforts to design a coronavirus vaccine have focused on a variety of approaches including development of inactivated virus, live-attenuated virus, and a variety of subunit vaccines. | ||
Source: https://www.mdpi.com/1999-4915/6/7/2531 | <small>Source: https://www.mdpi.com/1999-4915/6/7/2531</small> | ||
All coronavirus vaccine candidates are directed against the Spike protein (S protein), the most immunological component of coronaviruses. | All coronavirus vaccine candidates are directed against the Spike protein (S protein), the most immunological component of coronaviruses. | ||
Source: https://www.mdpi.com/2414-6366/4/1/31 | <small>Source: https://www.mdpi.com/2414-6366/4/1/31</small> | ||
===Examples=== | ===Examples=== | ||
<blockquote>The re-emergence of lethal coronaviruses calls for international collaboration to produce coronavirus vaccines, which are still lacking to date. </blockquote>Source: https://www.sciencedirect.com/science/article/pii/S1879625716301481?via%3Dihub<blockquote>They summarize the challenges of developing a successful, protective coronavirus vaccine, especially for SARS-CoV.</blockquote>Source: https://www.futuremedicine.com/doi/10.2217/17460794.3.2.119 | <blockquote>The re-emergence of lethal coronaviruses calls for international collaboration to produce '''coronavirus vaccines''', which are still lacking to date. </blockquote><small>Source: https://www.sciencedirect.com/science/article/pii/S1879625716301481?via%3Dihub</small><blockquote>They summarize the challenges of developing a successful, protective '''coronavirus vaccine''', especially for SARS-CoV.</blockquote><small>Source: https://www.futuremedicine.com/doi/10.2217/17460794.3.2.119</small> | ||
=== Collocations === | === Collocations === | ||
* novel | * novel coronavirus vaccine | ||
* develop | * develop coronavirus vaccine | ||
* efficient | * efficient coronavirus vaccine | ||
* efficacious | * efficacious coronavirus vaccine | ||
* live / killed | * live / killed coronavirus vaccine | ||
* | * coronavirus vaccine development | ||
* | * coronavirus vaccine candidate | ||
* | * | ||
===Keyness=== | ===Keyness=== | ||
> 1000 | |||
* coronavirus vaccine: >1000 | |||
* COVID-19 vaccine: >1000 | |||
* SARS-CoV-2 vaccine: >1000 | |||
===Note=== | ===Note=== | ||
Revision as of 18:00, 22 January 2022
Research
Variants and synonyms
- COVID-19 vaccine
- SARS-CoV-2 vaccine
Definition/description
Efforts to design a coronavirus vaccine have focused on a variety of approaches including development of inactivated virus, live-attenuated virus, and a variety of subunit vaccines.
Source: https://www.mdpi.com/1999-4915/6/7/2531
All coronavirus vaccine candidates are directed against the Spike protein (S protein), the most immunological component of coronaviruses.
Source: https://www.mdpi.com/2414-6366/4/1/31
Examples
The re-emergence of lethal coronaviruses calls for international collaboration to produce coronavirus vaccines, which are still lacking to date.
Source: https://www.sciencedirect.com/science/article/pii/S1879625716301481?via%3Dihub
They summarize the challenges of developing a successful, protective coronavirus vaccine, especially for SARS-CoV.
Source: https://www.futuremedicine.com/doi/10.2217/17460794.3.2.119
Collocations
- novel coronavirus vaccine
- develop coronavirus vaccine
- efficient coronavirus vaccine
- efficacious coronavirus vaccine
- live / killed coronavirus vaccine
- coronavirus vaccine development
- coronavirus vaccine candidate
Keyness
- coronavirus vaccine: >1000
- COVID-19 vaccine: >1000
- SARS-CoV-2 vaccine: >1000